OC
TEVA icon

Optimas Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Optimas Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-163,400
Closed -$2.51M – 29
2025
Q1 		$2.51M Buy
+163,400
New +$2.92M 4.27% 9

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Optimas Capital's TEVA Position: Q2 2025 in Review

Optimas Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 163,400 shares — an estimated $2.51M sold.

Optimas Capital first reported a position in TEVA in Q1 2025 and held it in 1 quarter. The position peaked at $2.51M in Q1 2025. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Optimas Capital reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Optimas Capital sold 163,400 Teva Pharmaceuticals shares in Q2 2025, an estimated $2.51M.
  • Optimas Capital first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Optimas Capital's Teva Pharmaceuticals position peaked at $2.51M in Q1 2025.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Optimas Capital's 13F filing for Q2 2025, filed 13 Aug 2025.